|
Name |
Arisugacin J
|
Molecular Formula | C27H32O8 | |
IUPAC Name* |
(1S,2S,5R,7R,10R)-1,5,7-trihydroxy-14-(4-methoxyphenyl)-2,6,6,10-tetramethyl-11,15-dioxatetracyclo[8.8.0.02,7.012,17]octadeca-12(17),13-diene-3,16-dione
|
|
SMILES |
C[C@@]12CC[C@@]3([C@@]([C@]1(CC4=C(O2)C=C(OC4=O)C5=CC=C(C=C5)OC)O)(C(=O)C[C@H](C3(C)C)O)C)O
|
|
InChI |
InChI=1S/C27H32O8/c1-23(2)20(28)13-21(29)25(4)26(23,31)11-10-24(3)27(25,32)14-17-19(35-24)12-18(34-22(17)30)15-6-8-16(33-5)9-7-15/h6-9,12,20,28,31-32H,10-11,13-14H2,1-5H3/t20-,24-,25+,26-,27-/m1/s1
|
|
InChIKey |
OQZMMSBLGYHONG-ZJQFWPFFSA-N
|
|
Synonyms |
CHEMBL4440372; Arisugacin J; Arisugacin O; BDBM50530476
|
|
CAS | NA | |
PubChem CID | 102132271 | |
ChEMBL ID | CHEMBL4440372 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 484.5 | ALogp: | 1.7 |
HBD: | 3 | HBA: | 8 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 123.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 35 | QED Weighted: | 0.592 |
Caco-2 Permeability: | -5.12 | MDCK Permeability: | 0.00001410 |
Pgp-inhibitor: | 0.316 | Pgp-substrate: | 0.994 |
Human Intestinal Absorption (HIA): | 0.216 | 20% Bioavailability (F20%): | 0.831 |
30% Bioavailability (F30%): | 0.897 |
Blood-Brain-Barrier Penetration (BBB): | 0.801 | Plasma Protein Binding (PPB): | 82.06% |
Volume Distribution (VD): | 1.075 | Fu: | 12.22% |
CYP1A2-inhibitor: | 0.735 | CYP1A2-substrate: | 0.934 |
CYP2C19-inhibitor: | 0.809 | CYP2C19-substrate: | 0.645 |
CYP2C9-inhibitor: | 0.808 | CYP2C9-substrate: | 0.257 |
CYP2D6-inhibitor: | 0.082 | CYP2D6-substrate: | 0.428 |
CYP3A4-inhibitor: | 0.809 | CYP3A4-substrate: | 0.794 |
Clearance (CL): | 7.064 | Half-life (T1/2): | 0.104 |
hERG Blockers: | 0.103 | Human Hepatotoxicity (H-HT): | 0.705 |
Drug-inuced Liver Injury (DILI): | 0.868 | AMES Toxicity: | 0.028 |
Rat Oral Acute Toxicity: | 0.978 | Maximum Recommended Daily Dose: | 0.941 |
Skin Sensitization: | 0.113 | Carcinogencity: | 0.962 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.008 |
Respiratory Toxicity: | 0.971 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003231 | 0.725 | D06XZW | 0.257 | ||||
ENC002037 | 0.632 | D0N0RU | 0.250 | ||||
ENC003130 | 0.573 | D0P1UX | 0.248 | ||||
ENC000932 | 0.560 | D04UTT | 0.245 | ||||
ENC002118 | 0.399 | D09WKB | 0.242 | ||||
ENC002102 | 0.392 | D06HBQ | 0.238 | ||||
ENC003423 | 0.388 | D06GCK | 0.233 | ||||
ENC003422 | 0.388 | D07MGA | 0.228 | ||||
ENC002412 | 0.368 | D02DPU | 0.228 | ||||
ENC005020 | 0.365 | D0Q0PR | 0.223 |